Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

• Status: Completed
• Trial end date: 2015-11-23
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Ranibizumab

Criteria

Key Inclusion criteria:

• Patients with visual impairment due to neovascular AMD

• A qualifying vision score at study entry Key Exclusion criteria

• Active infection or inflammation either eye at study entry

• Uncontrolled glaucoma in either eye

• Any disorder in the study eye which may affect vision

• Use of any systemic anti-vascular endothelial growth factor (VEGF)-drugs within 3 months prior to study entry

• Previous treatment of the study eye for wet AMD

• Any surgery in the study eye 3 months prior to or planned with 6 month after study entry